Loading organizations...
Raydiant Oximetry, Inc. has raised $21.5M across 4 funding rounds.
Key people at Raydiant Oximetry, Inc..
Raydiant Oximetry, Inc. has raised $21.5M in total across 4 funding rounds.
Raydiant Oximetry, Inc. is a clinical-stage medical device company dedicated to advancing fetal health monitoring through innovative technology. The company develops sophisticated solutions leveraging world-class sensor design and signal processing expertise, specifically in pulse oximetry, to provide enhanced insights into fetal well-being. Their core offering aims to provide safer pregnancies and improved maternal and fetal care, focusing on critical moments during childbirth.
The company was founded by Neil Ray, MD, who assumed the role of CEO and Founder in January 2016. Dr. Ray established Raydiant Oximetry based on the critical insight that existing monitoring methods could be significantly enhanced to better ensure the safety of women and babies during labor and delivery. His background and the team's collective expertise in medical device innovation laid the groundwork for pursuing this vital mission.
Raydiant Oximetry's product is designed for use by healthcare providers to monitor mothers and babies throughout the childbirth process. The company’s long-term vision is to fundamentally improve the safety and outcomes for women and infants globally by providing more accurate and timely information. They aspire to become a standard of care in maternal and fetal health monitoring, enhancing the birthing experience for all.
Raydiant Oximetry, Inc. has raised $21.5M across 4 funding rounds. Most recently, it raised $7.5M Raydiant Oximetry - Series A Extension in June 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jun 4, 2024 | $7.5M Series A Plus | Cross Border Impact Ventures | — | Announced |
| Jun 1, 2024 | $8M Series A | — | Avestria Ventures, Global Health Impact Fund | Announced |
| Nov 3, 2021 | $5M Series A | Avestria Ventures | — | Announced |
| Sep 13, 2018 | $1M Seed | — | — | Announced |
Key people at Raydiant Oximetry, Inc..
Raydiant Oximetry, Inc. has raised $21.5M in total across 4 funding rounds.
Raydiant Oximetry, Inc.'s investors include Cross-Border Impact Ventures, Avestria Ventures, Global Health Impact Fund.
Raydiant Oximetry, Inc. is a clinical-stage medical device company developing Lumerah™, a noninvasive fetal pulse oximeter that directly measures oxygen levels in fetal blood from the mother's abdomen to detect distress during labor and improve outcomes for mothers and babies.[1][2][3][6] It serves obstetric providers and hospitals, addressing limitations of current electronic fetal monitoring, which has led to a 6-fold increase in U.S. cesarean deliveries over 50 years without reducing neonatal injuries, stillbirths, or cerebral palsy.[3] The company has raised over $8.2 million in funding, completed an Early Feasibility Study in October 2025, initiated an IDE Pilot Study in November 2025, and secured FDA Breakthrough Device status for accelerated approval, positioning it for market entry after a projected 10-year, $30 million development journey.[1][2][3]
Founded in 2015 by Neil P. Ray, MD, an anesthesiologist practicing since 2005, Raydiant Oximetry emerged from Ray's clinical observations of unmet needs in labor and delivery monitoring.[1][2] Lacking engineering or business expertise, Ray pitched his idea to the Fogarty Institute for Innovation, a Bay Area nonprofit medical device accelerator, which provided crucial early support.[1] The company built on established pulse oximetry technology—highlighted during COVID-19 for skin tone accuracy issues—to create a fetal-specific solution, securing initial SBIR funding and grants like $3 million from the Irish government.[1][3] Pivotal early traction included a $5.6 million Series A led by VCapital and graduation from Fogarty, fueling preclinical trials showing improved distress detection.[1][3]
Raydiant rides the wave of precision maternal-fetal medicine, leveraging biophotonics, AI-driven signal processing, and noninvasive wearables to overhaul 50-year-old fetal monitoring amid U.S. maternal mortality crises and global childbirth risks.[1][3] Timing aligns with post-COVID scrutiny of pulse oximetry biases, heightened investor interest in women's health (e.g., Series B kickoff via March of Dimes), and regulatory support like FDA Breakthrough designation.[1][3] Market forces favor it: demand for better distress detection to cut cesareans (now over 30% in the U.S.), grants from Gates Foundation and governments signal public health priority, and collaborations like GE HealthCare amplify scale.[3] By succeeding, Raydiant could influence ecosystems, drawing capital to women's and children's health tech, where unmet needs persist despite critical stakes.[1]
Raydiant is poised for Series B expansion and pivotal trials post-2025 milestones, targeting market entry in 3-5 years with $20 million more needed to hit $30 million total investment.[1][3] Trends like AI-enhanced diagnostics, equitable medtech (addressing skin tone issues), and global health equity will propel it, especially via partnerships and grants.[1][3] Its influence may evolve from pioneer to standard-of-care setter, lifting investment tides for maternal innovations and safer births worldwide—transforming Ray's bedside insight into a tide-rising success.[1]
